Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API

By D. McNamara, S. Childs, J. Giordano, Anthony Iarriccio, J. Cassidy, M. Shet, R. Mannion, E. O'donnell, A. Park. Pharmaceutical Research, 2006

636 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability (2014, background): “The use of the co e crystal increased the aqueous dissolution rate by up to 18 times as compared to the homo-meric crystalline form of the same drug [45].”
Strategies to Address Low Drug Solubility in Discovery and Development (2013, methodology): “tometry is also increasingly being used to determine structural details of the cocrystal (McNamara et al., 2006; Remenar et al., 2007), and NMR and HPLC are being used to verify the stoichiometric ratio of the complex (Bak et al.”
Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. (2007, background): “[114] have shown the potential benefits of co-crystal formation on drug dissolution and bioavailability, this embryonic area of pharmaceutical research is still relatively unexplored and requires further study before co-crystals can be considered to be a reliable toolbox technology for the enhanceme”